U.S. markets close in 4 hours 47 minutes

Public Joint-Stock Company "Human Stem Cells Institute"'s (MCX:ISKJ) Stock Is Going Strong: Is the Market Following Fundamentals?

Simply Wall St

Most readers would already be aware that Human Stem Cells Institute's (MCX:ISKJ) stock increased significantly by 128% over the past three months. Since the market usually pay for a company’s long-term fundamentals, we decided to study the company’s key performance indicators to see if they could be influencing the market. In this article, we decided to focus on Human Stem Cells Institute's ROE.

ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.

View our latest analysis for Human Stem Cells Institute

How To Calculate Return On Equity?

Return on equity can be calculated by using the formula:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Human Stem Cells Institute is:

30% = ₽111m ÷ ₽371m (Based on the trailing twelve months to December 2019).

The 'return' refers to a company's earnings over the last year. That means that for every RUB1 worth of shareholders' equity, the company generated RUB0.30 in profit.

Why Is ROE Important For Earnings Growth?

Thus far, we have learnt that ROE measures how efficiently a company is generating its profits. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming all else is equal, companies that have both a higher return on equity and higher profit retention are usually the ones that have a higher growth rate when compared to companies that don't have the same features.

Human Stem Cells Institute's Earnings Growth And 30% ROE

To begin with, Human Stem Cells Institute has a pretty high ROE which is interesting. Additionally, the company's ROE is higher compared to the industry average of 17% which is quite remarkable. So, the substantial 29% net income growth seen by Human Stem Cells Institute over the past five years isn't overly surprising.

We then compared Human Stem Cells Institute's net income growth with the industry and we're pleased to see that the company's growth figure is higher when compared with the industry which has a growth rate of 20% in the same period.

MISX:ISKJ Past Earnings Growth May 17th 2020

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is Human Stem Cells Institute fairly valued compared to other companies? These 3 valuation measures might help you decide.

Is Human Stem Cells Institute Using Its Retained Earnings Effectively?

Human Stem Cells Institute doesn't pay any dividend currently which essentially means that it has been reinvesting all of its profits into the business. This definitely contributes to the high earnings growth number that we discussed above.

Conclusion

On the whole, we feel that Human Stem Cells Institute's performance has been quite good. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. If the company continues to grow its earnings the way it has, that could have a positive impact on its share price given how earnings per share influence long-term share prices. Not to forget, share price outcomes are also dependent on the potential risks a company may face. So it is important for investors to be aware of the risks involved in the business. Our risks dashboard would have the 4 risks we have identified for Human Stem Cells Institute.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.